Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician

Nathalie Cristina Crivelari,Gisele Queiroz De Oliveira,Ludhmila Abrahão Hajjar,Francisco Carlos Da Costa Darrieux,Glaucia Maria Moraes De Oliveira,Clarice Hyesuk Lee Park,Marcus Vinícius Guimarães De Lacerda,Luciana Sacilotto,Isabela Bispo Santos Da Silva Costa,Gregorio Da Cruz Riemma

doi:10.36660/ijcs.20200125

Nathalie Cristina Crivelari, Gisele Queiroz De Oliveira + Show 8 more

Open Access

https://doi.org/10.36660/ijcs.20200125

Copy DOI

Abstract

Introduction Since December 31, 2019, when China reported the appearance of cases of acute respiratory failure caused by a new species of coronavirus, SARS-CoV-2, which causes the disease called COVID-19, almost 20 million cases were confirmed, causing 726 thousand deaths worldwide. In Brazil, on August 8th, 2020, there was approximately 3 million cases and 100 thousand death by the disease. Its rapid spread, its high potential for hospitalization, and its high lethality, especially in the most fragile groups such as [...]

Highlights

Since December 31, 2019, when China reported the appearance of cases of acute respiratory failure caused by a new species of coronavirus, SARS-CoV-2, which causes the disease called COVID-19, almost 20 million cases were confirmed, causing 726 thousand deaths worldwide.[1]
The medications used are described in case records, with no solid scientific evidence for their use, and with a COVID-19/complications; Pandemics; Betacoronavirus; Cardiovascular Diseases/complications; Arrhythmias, Cardiac; Stroke Volume; Death, Sudden; Chloroquine; Hydroxychloroquine; Azythromycin
It was demonstrated that approximately 20% of patients with COVID-19 have myocardial injury, 10% have myocarditis, and 10 to 30% evolve with shock,[18] which would multiply the probability of adverse effects in a proinflammatory and pro-thrombotic environment

Summary

Introduction

Since December 31, 2019, when China reported the appearance of cases of acute respiratory failure caused by a new species of coronavirus, SARS-CoV-2, which causes the disease called COVID-19, almost 20 million cases were confirmed, causing 726 thousand deaths worldwide.[1]. It is observed that the highest incidence of events occurs in people with other predisposing factors, such as long QT syndrome, structural cardiovascular diseases, or the use of other drugs that prolong QT.[17] In addition, it was demonstrated that approximately 20% of patients with COVID-19 have myocardial injury, 10% have myocarditis, and 10 to 30% evolve with shock,[18] which would multiply the probability of adverse effects in a proinflammatory and pro-thrombotic environment These patients possibly have greater substrates for arrhythmia and electrolyte disturbances, and still in the critical phase of the disease, most patients admitted to intensive care units are treated with multiple combined therapies, such as vasoactive amines, diuretics, and serotonin 5-ht[3] receptor antagonists, among others.

Mechanical ventilation

Findings

Author Contributions